Lundbeck begins phase II trial of antibody for migraine prevention
Antibody treatment Lu AG09222 will be tested in a phase II trial including around 230 patients, the company reports. The candidate uses a different mechanism than the relatively new class of CGRP receptors, which have been gaining ground on the migraine market.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
A few days after receiving pivotal European approval for its migraine drug Vyepti, Lundbeck is moving ahead with another candidate for the treatment of migraines.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.